161 related articles for article (PubMed ID: 34814056)
41. Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.
Miró G; Gálvez R; Fraile C; Descalzo MA; Molina R
Parasit Vectors; 2011 Apr; 4():52. PubMed ID: 21489241
[TBL] [Abstract][Full Text] [Related]
42. Value of Western blotting in the clinical follow-up of canine leishmaniasis.
Fernández-Pérez FJ; Méndez S; de la Fuente C; Cuquerella M; Gómez MT; Alunda JM
J Vet Diagn Invest; 1999 Mar; 11(2):170-3. PubMed ID: 10098690
[TBL] [Abstract][Full Text] [Related]
43. Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
de Jong MK; Rappoldt A; Broere F; Piek CJ
Parasit Vectors; 2023 May; 16(1):163. PubMed ID: 37189181
[TBL] [Abstract][Full Text] [Related]
44. Leishmania infantum-specific IFN-γ production in stimulated blood from dogs with clinical leishmaniosis at diagnosis and during treatment.
Martínez-Orellana P; Marí-Martorell D; Montserrat-Sangrà S; Ordeix L; Baneth G; Solano-Gallego L
Vet Parasitol; 2017 Dec; 248():39-47. PubMed ID: 29173539
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of polymorphonuclear cell and monocyte functions in Leishmania infantum-infected dogs.
Brandonisio O; Panunzio M; Faliero SM; Ceci L; Fasanella A; Puccini V
Vet Immunol Immunopathol; 1996 Sep; 53(1-2):95-103. PubMed ID: 8941972
[TBL] [Abstract][Full Text] [Related]
46. Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
Dias ÁFLR; Ayres EDCBS; de Oliveira Martins DT; Maruyama FH; de Oliveira RG; de Carvalho MR; Almeida ADBPF; Teixeira ALS; Mendonça AJ; Sousa VRF
Exp Parasitol; 2020 Oct; 217():107947. PubMed ID: 32628971
[TBL] [Abstract][Full Text] [Related]
47. Short term impacts of meglumine antimoniate treatment on kidney function in dogs with clinical leishmaniosis.
Daza González MA; Miró G; Fermín Rodríguez M; Rupérez Noguer C; Fragío Arnold C
Res Vet Sci; 2019 Oct; 126():131-138. PubMed ID: 31491669
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: A randomized, blinded, controlled study.
Kasabalis D; Chatzis MK; Apostolidis K; Xenoulis PG; Buono A; Petanides T; Leontides LS; Polizopoulou ZS; Steiner JM; Suchodolski JS; Saridomichelakis MN
Exp Parasitol; 2019 Nov; 206():107768. PubMed ID: 31539540
[TBL] [Abstract][Full Text] [Related]
49. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
Chapman WL; Hanson WL; Alving CR; Hendricks LD
Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
[TBL] [Abstract][Full Text] [Related]
50. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.
Corpas-López V; Merino-Espinosa G; Acedo-Sánchez C; Díaz-Sáez V; Navarro-Moll MC; Morillas-Márquez F; Martín-Sánchez J
Vet Res Commun; 2018 Jun; 42(2):121-130. PubMed ID: 29453596
[TBL] [Abstract][Full Text] [Related]
52. Short report: improved diagnosis and follow-up of canine leishmaniasis using amastigote-based indirect immunofluorescence.
Fernández-Pérez FJ; Méndez S; de la Fuente C; Gómez-Muñoz MT; Cuquerella M; Alunda JM
Am J Trop Med Hyg; 1999 Oct; 61(4):652-3. PubMed ID: 10548304
[TBL] [Abstract][Full Text] [Related]
53. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
54. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
55. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs.
Bourdoiseau G; Bonnefont C; Hoareau E; Boehringer C; Stolle T; Chabanne L
Vet Immunol Immunopathol; 1997 Oct; 59(1-2):21-30. PubMed ID: 9437823
[TBL] [Abstract][Full Text] [Related]
56. CD4
Vieira JFP; de Oliveira Cardoso JM; de Brito RCF; Roatt BM; Carneiro CM; Valadares DG; de Oliveira Aguiar-Soares RD; Reis AB
Mol Immunol; 2022 Nov; 151():61-69. PubMed ID: 36087461
[TBL] [Abstract][Full Text] [Related]
57. First Report of an Urban Case of Canine Visceral Leishmaniasis in the Municipality of Cali, Colombia.
Arbeláez N; Moreno J; Murillo J; Montoya A; Robledo SM; Vélez A; Vélez ID
Am J Trop Med Hyg; 2020 Feb; 102(2):289-293. PubMed ID: 31802736
[TBL] [Abstract][Full Text] [Related]
58. Seizures as a Consequence of Hyperviscosity Syndrome in Two Dogs Naturally Infected with Leishmania infantum.
Proverbio D; Spada E; Perego R; de Giorgi GB
J Am Anim Hosp Assoc; 2016; 52(2):119-23. PubMed ID: 26808431
[TBL] [Abstract][
